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Abstract   
BACKGROUND: Patients with REM sleep behavior disorder (RBD) have a high risk of 
developing PD, and thus can be used to study prodromal biomarkers. RBD has been associated 
with changes in gait; quantifying these changes using wearable technology is promising; however, 
most data are obtained in clinical settings precluding pragmatic application.  
OBJECTIVE: We aimed to investigate if wearable-based real-world gait monitoring can detect 
early gait changes and discriminate individuals with RBD from controls, and explore relationships 
between real-world gait and clinical characteristics. 
METHODS: 63 individuals with RBD (66±10 years) and 34 controls recruited in the Oxford 
Parkinson’s Disease Centre Discovery Study were assessed. Data were collected using a wearable 
device positioned on the lower back for 7 days. Real-world gait was quantified in terms of its 
Macrostructure (volume, pattern and variability (S2)) and Microstructure (14 characteristics).  The 
value of Macro and Micro gait in discriminating RBD from controls was explored using ANCOVA 
and ROC analysis, and correlation analysis was performed between gait and clinical 
characteristics. 
RESULTS: Significant differences were found in discrete Micro characteristics in RBD with 
reduced gait velocity, variability and rhythm (p≤0.023). These characteristics significantly 
discriminated RBD (AUC≥0.620), with swing time as the single strongest discriminator 
(AUC=0.652). Longer walking bouts discriminated best between the groups for Macro and Micro 
outcomes (p≤0.036). 
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CONCLUSIONS: Our results suggest that real-world gait monitoring may have utility as “risk” 
clinical marker in RBD participants. Real-world gait assessment is low-cost and could serve as a 
pragmatic screening tool to identify gait impairment in RBD. 
Introduction 
Parkinson’s disease (PD) is a progressive multisystem syndrome. There is no cure, and great 
efforts are underway to discover disease modifying therapies. It is estimated that by the time of 
diagnosis striatal dopamine is depleted by approximately 70-80%, a figure that corresponds to cell 
death of 30-50% of dopaminergic neurons in the substantia nigra [1, 2].  Recent clinicopathological 
work has demonstrated that loss of dopaminergic markers in the putamen is complete by four years 
post-diagnosis, highlighting the importance of early targeted therapy if disease modification is to 
be prioritized [3]. 
Diagnosis is therefore preceded by a long prodromal period during which the disease process has 
started but definitive motor symptoms and signs to permit a diagnosis have not yet appeared [4]. 
This period has been estimated, by retrospective and prospective studies, to vary between three to 
more than 20 years [2, 5, 6]. If we wish to address disease modification, early intervention during 
the prodromal period would be ideal to slow or halt ongoing degeneration of neurons. Identifying 
robust prodromal clinical and other biomarkers during this period is therefore an area of intense 
research interest. 
Idiopathic Rapid Eye Movement Sleep Behaviour Disorder (RBD) is of particular interest as a 
prodromal marker. More than 80% of RBD patients convert to PD or another α-synucleinopathy 
with a median overall prodromal phase of 8 years [7], and a motor phase of 4.5 years [4, 8, 9]. A 
very recent study estimated an overall conversion rate from RBD to an overt neurodegenerative 
syndrome of 6.3% per year, with 73.5% converting after 12-year follow-up [7], with an estimated 
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prevalence of RBD in PD of 42.3% in PD [10]. Previous studies have also reported a male pre-
dominance in typical RBD, with more than 80% of the patients being male [11, 12].  
Postuma et al. demonstrated that, using simple motor assessments (Movement Disorders Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) and Timed Up and Go test), abnormalities in 
gait can precede PD diagnosis by up to 4.4-6.3 years [4]. McDade et al. have shown that 
quantitative cross-sectional analysis of normal pace walking in RBD participants found subtle 
changes of velocity, cadence and variability of gait compared to controls [13]. A recent paper 
showed also differences in gait between RBD participants and controls during fast and dual task 
conditions in a laboratory environment [14].  
Gait may therefore be a useful clinical biomarker to identify risk of conversion in RBD. Both 
studies, however, were performed under controlled conditions, with one study requiring 
specialized equipment (e.g. instrumented walkway) limiting its application. To address this 
shortcoming, wearable technology that measures discrete movements has been employed with 
promising findings. 
Recently, selective gait characteristics measured with wearable technology have been shown to be 
potential prodromal markers for people at risk of PD [15] and also in LRRK2 mutation carriers 
[16]. People at risk of PD and carriers demonstrated increased gait variability and asymmetry [15], 
a less consistent and rhythmic gait pattern (lower amplitude of the dominant peak of the 
accelerometer signal) [16], although these studies again were conducted in laboratory-based 
settings during controlled conditions. Intriguingly, work in RBD using smartphone technology in 
free-living conditions and prompted, structured tasks found that postural tremor, rest tremor, and 
voice were the discriminatory domains between RBD and controls but not gait, although signal 
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features (e.g. frequency-based features, detrended fluctuation analysis, etc.) rather than more 
clinically relevant, specific gait characteristics were quantified [17]. 
For wider scale screening, a more pragmatic, low cost method without the need for specialized 
staff or equipment is needed. Continuous monitoring in the real-world using wearable technology 
offers a solution with the added advantage that it avoids potential confounding due to 
compensation under controlled testing conditions and variation due to one-off sporadic 
assessments. It also provides a more ecological representation of gait and walking activity in a 
natural environment often implying ‘real-world dual-task’ conditions. This technology may thus 
serve as a tool to accurately identify surrogate markers of incipient disease manifestation [16-19]. 
The aims of this study were therefore: (i) to investigate if it was possible to detect subtle prodromal 
gait disturbances using continuous real-world monitoring with a wearable device and if this could 
discriminate RBD from a control group; and (ii) to explore the relationship between discriminatory 
gait characteristics with clinical scales associated with RBD. We adopted a comprehensive 
approach to quantify gait using a combination of Macrostructural (Macro) and Microstructural 
(Micro) gait characteristics.  Based upon the only other quantitative study of gait in RBD [13, 16, 
20] we hypothesized that people with RBD would have reduced volume of walking activity, and 
would demonstrate impairment in gait characteristics such as slower velocity, increased Micro gait 
variability and lower cadence compared to controls.  
Methods 
2.1 Participants 
RBD participants and controls (CL) were enrolled in the Oxford Parkinson’s Disease Centre 
(OPDC) Discovery study [21, 22]. The diagnosis of RBD was made on the basis of 
polysomnographic evidence according to the American Academy of Sleep Medicine International 
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Classification of Sleep Disorders criteria [23]. Full details of the clinical protocol and inclusion 
and exclusion criteria are described in detail elsewhere [21, 24]. 
 
2.2 Ethics, consent and permissions 
This study was conducted according to the declaration of Helsinki and had ethical approval from 
the local research committee (NRES Committee, South Central Oxford A Research Ethics 
Committee, Reference number 16/SC/0108). All participants gave written informed consent prior 
to testing. 
 
2.3 Demographic and clinical measures 
Age, gender and BMI were recorded for each participant. A comprehensive, structured medical 
history was taken from all participants including comorbidities and demographic information. 
Cognition was assessed using the Mini-Mental State Examination (MMSE [25]). EQ-5D was used 
as a standardized self-report measure of health status [26] and excessive daytime somnolence was 
measured by the Epworth Sleepiness Scale [27]. Motor features were assessed using: MDS-
UPDRS part III (MDS-UPDRS-III) [28]; the Purdue Pegboard test [29]; the Flamingo test (the 
ability of the patient to balance on one leg for 30 seconds) and the Timed Up and Go Test [24, 30]. 
The probability of prodromal PD was calculated for each participant at their baseline assessment 
using the method described by Berg et al. [31] as detailed in [21]. The following risk markers were 
used: sex, pesticide exposure, solvent exposure, caffeine use, smoking history, family history of 
PD, and presence of gene mutation (GBA or LRRK2). The following prodromal markers were 
also included: presence of RBD confirmed by polysomnography, subthreshold parkinsonism 
(using UPDRS and Purdue Pegboard scores), olfactory loss, constipation, excessive daytime 
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somnolence (measured by the Epworth Sleepiness Scale), postural hypotension, urinary 
dysfunction, and depression/anxiety [21]. Falls Rate was collected as the number of falls self-
reported in the six months prior to the assessment. 
2.4 Free-living data collection: protocol 
Participants were asked to wear a tri-axial accelerometer (Axivity AX3, York, UK; dimensions: 
23.0 × 32.5 × 7.6 mm; weight: 11 grams) for one week [32]. The device has been validated for its 
suitability in capturing high-resolution data akin to human movement [33]. It was located on the 
fifth lumbar vertebrae with a hydrogel adhesive (PAL Technologies, Glasgow, UK) and covered 
with additional tape (Hypafix bandage) for extra support. The water-proof device was programmed 
to capture data for seven days at 100Hz (range ± 8g). Participants were asked to continue their 
daily activities as usual and not to change their routine. Upon completion of the recording, 
participants removed the device and posted it back to the researcher as detailed in previous work 
[34]. 
 
2.5 Data processing and analysis 
2.5.1 Data processing and variable extraction 
Once the wearable device was collected by the researcher, data were uploaded to a secure online 
platform for automatic data analysis. The pipeline has been developed using e-Science Central, a 
password-protected cloud based platform that allows the storage, analysis and sharing of data in 
the cloud. Analysis of data was carried out via the e-Science platform using an executable of 
validated MATLAB® scripts [35, 36] thereby generating a closed standalone analysis package. 
Data were segmented (per calendar day) and analyzed. For each day, a logical heuristics paradigm 
was embedded into walking bout identification and quantification algorithm which has shown to 
9 
 
be accurate in detecting ambulatory bouts (ABs) and step count in free-living conditions [36]. 
Individual ABs were extracted, where a ‘bout’ was defined as the continuous length of time spent 
walking with at least four consecutive steps [34, 36]. ABs were detected by applying selective 
thresholds on the magnitude and standard deviation (SD) of the triaxial acceleration data as 
described in detail elsewhere [36]. 
Outcome measures were described according to a broad framework of Macro and Micro 
characteristics [37] (Figure 1).  
Macro (behavioral) characteristics included the volume, pattern and variability (S2) of walking. 
Volumetric outcomes included total walking time per day, percentage (%) of walking time per 
day, number of bouts and steps per day. Pattern included mean bout length, generated based on 
the AB detected over the 7 days, and a non-linear descriptor (alpha (α)). Alpha describes ABs 
distribution, evaluating the ratio of short to long ABs (i.e. a high alpha means that the total walking 
time is made up of proportionally short ABs compared to long ABs). Macro gait variability (S2) 
was derived evaluating the ‘within subject’ variability of AB length, with a higher Macro gait 
variability (S2) indicating a more varied walking activity pattern, while a lower Macro gait 
variability (S2) would mean a less varied walking activity, so a reduced engagement in different 
activity and a tendency to repeat the same pattern of activity [34, 38, 39].  
Micro gait characteristics (n=14) were determined for each AB. Micro characteristics were 
selected based upon a model of gait comprising five domains (pace, variability, rhythm, 
asymmetry and postural control) validated both in older adults and in PD [33, 40]. Briefly, the 
initial contact and final contact events within the gait cycle were identified and allowed the 
estimation of step, stance and swing time. Initial contact events were also used to estimate step 
length using the inverted pendulum model [41]. Step velocity was calculated as the ratio between 
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step length and time [33].To evaluate micro gait variability (e.g. step time variability), the standard 
deviation (SD) from all steps (left and right combined) was calculated. Asymmetry was determined 
as the absolute difference between left and right steps for each AB, averaged across all ABs [33, 
42]. 
2.5.2 Data considerations 
All ABs with more than three steps (minimum bout length) were taken into account for the analysis 
[43-46]. A threshold of 2.5 seconds was set for the maximum resting period between consecutive 
ABs [36]. Each AB was considered individually to ensure robustness for the evaluation of the gait 
characteristics, to avoid sources of error in step detection, and facilitate the calculation of 
variability and asymmetry characteristics [19]. Micro outcomes were evaluated for each single AB 
and then averaged over the seven days; pooled seven-day data were used for quantifying Macro 
outcomes. As exploratory analysis Macro and Micro outcomes were evaluated including all ABs 
greater than three steps, and also including only short-to-medium (10s ≤ ABs < 30s, corresponding 
to a range of 15-50 steps), medium to long (30s ≤ ABs < 60s, , corresponding to a range of 50-100 
steps) and long ambulatory bouts (ABs ≥ 60s, corresponding to ≥100 steps) [19, 36, 47]. 
 
2.5.3 Statistical analysis 
Statistical analysis was carried out using SPSS v24 (IBM). Normality of data was tested with a 
Shapiro-Wilk test. Descriptive statistics were reported as means and SDs.  
(i) To distinguish between RBD and control cohorts we used a two-stage approach.  
1.  We identified between-group Macro and Micro gait differences in RBD vs. control 
participants with analysis of covariance (ANCOVA); age, sex, MMSE, MDS-UPDRS II 
and III and BMI were included as covariates. Further analysis of Micro and Macro 
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outcomes was then repeated on walking bouts grouped by bout length (short-to-medium 
(10s ≤ ABs < 30s), medium to long (30s ≤ ABs < 60s) and long ambulatory bouts (ABs ≥ 
60s)), to explore the impact of AB length on results. 
2. Secondary analysis explored the value of Micro and Macro gait characteristics for 
discriminating people with RBD from controls. Receiver Operating Characteristics (ROC) 
and stepwise, forward, logistic regression analyses controlling for age, sex and BMI were 
performed. All Micro gait characteristics were considered candidates and parameters were 
entered in the regression model. Discriminative models and Micro gait characteristics with 
the highest Area Under the Curve (AUC) for the ROC analysis are reported. Sensitivity for 
cut-off specificity at 90%, specificity for cut-off sensitivity at 90%, and best accuracy 
values of the variables and for the results of the regression models were also evaluated. 
Regression analysis was then repeated adding sniffin’ sticks total score to the Macro and 
Micro gait variables models, as olfactory loss has previously been shown to have a 
diagnostic specificity of >80% [48]. 
Given the exploratory nature of this analysis, we used a threshold of p < 0.05 to guide statistical 
interpretation and did not make adjustments for multiple comparisons [13, 49, 50]. However, we 
provide p-values and reported also p ≤ 0.01 so that the reader may assess the statistical strength of 
our findings. 
(ii) Finally, we explored the relationship between discriminatory characteristics and clinical and 
risk factors of conversion to PD in RBD participants to explain and interpret findings. We used 
Partial correlations controlling for age to identify relationships between Micro and Macro gait 
characteristics and clinical scales. 
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Results 
Sixty-three people with RBD and thirty-four controls were assessed. Clinical, demographic and 
cognitive descriptors are shown in Table 1. People with RBD and CL groups were comparable for 
age, BMI and gender (although RBD included proportionally, although not significantly, more 
women). In keeping with previous reports [21], RBD participants had lower cognitive, EQ-5D 
scores and sniffin’ sticks test total scores, and greater motor impairment as seen by MDS-UPDRS 
III scores. According to the MDS criteria 48 RBD participants met the MDS criteria for probable 
prodromal PD (Probability >80%). 
We also repeated the analysis looking at RBD at high risk (with MDS Probability of Prodromal 
PD > 80%) and at low risk (MDS Probability of Prodromal PD < 80%) and we did not found any 
significant differences in Macro or Micro gait characteristics between the two groups (p ≥ 0.137); 
these groups were therefore not reported separately. 
Those with RBD had also a higher number of falls reported in the six months prior to the 
assessment (Table 1).  
 
Differences in Macro gait characteristics between RBD and CL 
Between-group differences were influenced by bout length. When considering the total number of 
ABs no significant difference was found in Macro gait characteristics between people with RBD 
and CL. Volume of walking bouts did not differ between people with RBD and CL. There was a 
trend for people with RBD to walk in less variable (lower S2) ABs compared to CL, although this 
did not reach significance (Table 2, Figure 2a). 
When considering short-to-medium and medium-to long bouts again no differences were found 
between groups (Supplementary Table 1, Figure 3a and 3b).  
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However, when exploring differences based on long bouts (≥ 60s), although they represented less 
than 5% of the total amount of ABs, we found that ambulatory pattern significantly differed 
between the groups (Supplementary Table 1). Mean bout length was significantly lower and alpha 
significantly higher (denoting that walking time was made up proportionally of shorter ABs) for 
people with RBD compared to CL (p < 0.040) (Figure 3c).  
 
Differences in Micro gait characteristics between RBD and CL 
For total ABs, characteristics relating to pace (step velocity), variability (step velocity variability) 
and rhythm (step, stance and swing time) were significantly different between people with RBD 
and CL. People with RBD walked slower with less variable velocity. In addition, RBD had 
significantly slower cadence: higher step time, swing time and stance time compared to CL (Table 
3, Figure 2b). Interesting, postural control, as measured by step length asymmetry, did not 
discriminate between groups. 
For short-to-medium (10s ≤ ABs < 30s) and medium-to long ABs (30s ≤ ABs < 60s) we did not 
find any significant differences between the groups (Supplementary Table 2, Figure 3d and 3e). 
The picture remained similar to the one for total ABs. When considering long ABs (≥ 60s), again 
pace and rhythm resulted significantly lower for people with RBD compared to CL, although step 
velocity variability was no longer significant between the groups (p = 0.304) (Supplementary 
Table 2, Figure 3f).  
 
Discriminating prodromal gait disturbances within RBD with Macro and Micro gait 
characteristics. 
When looking at total ABs, none of the Macro characteristics discriminated RBD from CL. 
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For total ABs, step velocity and step velocity variability were the Micro gait characteristics that 
contributed to best discriminate individuals with RBD from CL with sensitivity of 88.9%, 
specificity of 31.4%, accuracy of 68.4% and AUC = 0.698 (Table 4). 
When olfactory loss (sniffin’ sticks test total scores) was added to the regression models for total 
ABs, AUC increased to 0.842, with sensitivity of 78.9%, specificity of 64.5% and accuracy of 
73.9% (Figure 4). 
For long ABs (≥ 60s), mean bout length, variability (S2) and alpha were the Macro gait 
characteristics which distinguished between the two groups. In addition, swing time was the 
characteristic which distinguished between individuals with RBD and CL with highest sensitivity 
of 93.70% (AUC = 0.652 as single variable and AUC = 0.660 for the regression model, Table 4). 
When sniffin’ sticks test total scores was added to the regression models for long ABs, AUC 
increased to 0.860 (highest value), with sensitivity of 78.9%, specificity of 67.7% and accuracy of 
75.0% (Figure 4). 
 
Relationship of Macro and Micro gait characteristics with clinical characteristics 
Partial correlation analysis between Macro gait characteristics and clinical scales showed a 
negative low to moderate correlation between volume, pattern and variability of walking and 
MDS-UPDRS III, denoting that people with more severe motor scores tended to walk less, in 
shorter bouts and with lower variability. We found that cognitive (MMSE) and health status tests 
(EQ-5D Score) significantly positively correlated with volume characteristics, showing that people 
with poorer cognition and worse health status walked less. In terms of motor tests, the Flamingo 
test showed a significant positive correlation with volume and pattern of walking and the Timed 
Up and Go Test showed negative correlations with volume, pattern and variability, showing that 
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participants with lower motor function walked less, in shorter and less variable bouts. Falls rate 
negatively correlated with volume and pattern of walking, suggesting that people with higher falls 
rate walked less and in shorter bouts (Table 5).  
Partial correlation analysis in RBD participants between Micro gait characteristics and clinical 
scales showed that MDS-UPDRS III scores significantly negatively correlated with pace (step 
velocity and step length) and positively with rhythm (step, swing and stance time), signifying that 
participants with higher score tended to walk slower and with shorter steps (Table 5). Cognitive 
tests (MMSE) showed a significant low to moderate positive correlation with pace and variability 
(step velocity variability), denoting that participants with poorer global cognitive scores walked 
slower and with lower variability. This finding is line with previous work demonstrating that global 
cognitive scores are associated with Micro gait pace (older adults) and variability characteristics 
(in PD) [51]. Our correlation findings, although exploratory, would corroborate the relationship 
between global cognition and gait (pace and step velocity variability characteristics) during the 
prodromal stage of PD, although requires validation in larger groups. 
Motor tests showed a significant positive correlation with pace and variability for the Flamingo 
test, and a negative correlation with pace and variability and a positive correlation with rhythm for 
the Timed Up and Go Test; showing how participants with lower motor functions walked slower 
and with lower variability (Table 5). 
The Epworth Sleepiness Scale Total Score and MDS Probability Score did not show any 
significant correlation with either Macro or Micro gait characteristics (Table 5). 
Discussion 
We provide here evidence that continuous, real-world gait assessment with wearable devices may 
be a good paradigm to identify prodromal Parkinsonian gait disturbances and risk of PD 
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conversion in people with RBD. Being aware that RBD may only reflect a subtype of (future) PD, 
our findings show discrete differences in gait informing a nuanced understanding of gait 
impairment during the prodromal PD stage. Macro gait characteristics demonstrated that pattern 
and walking bout length characteristics were associated with group only for long ABs. In contrast, 
we found that discrete Micro gait characteristics were able to discriminate between people with 
RBD and CL highlighting differences in pace, variability and rhythm, with swing time being the 
best discriminating characteristic for people with RBD.  
These findings highlight specific differences in Macro and Micro gait characteristics that may 
inform a pragmatic method for screening for risk of conversion to PD in RBD cohorts. Our study 
complements the existing evidence that there are subtle changes in gait prior to the onset of 
significant motor symptoms in an at risk group [9]. 
A novel aspect of this study is the real-world wearable device-based assessment of walking 
behaviour and gait impairments associated with RBD prior to the onset of clinically significant 
motor deficits and diagnosis of PD or dementia. This is the first study where data were collected 
with continuous passive monitoring in entirely uncontrolled environments, during every-day life, 
in a totally unconstrained way. Compliance was high and homogenous in both groups: 83.5% of 
the participants wore the accelerometer for the whole 7 day period, while 16.5% of the participants 
wore it for either 6 or 6.5 days. Reasons for the temporary removal of the accelerometer were 
travel and, for one participant, undergoing a CT scan. This presented a unique opportunity to 
observe whether Macro and Micro gait could detect prodromal gait disturbances in RBD, that may 
be able to flag people at risk of PD conversion. Moreover the significant association of clinical 
characteristics with gait lends validity to the findings. 
Walking activity (Macro gait) differs between RBD and CL only during long bouts. 
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Our findings only partly support our hypothesis that people with RBD are less active than CL. 
When looking at all walking bouts, we found that people with RBD were as active as and similar 
to CL when considering the total amount, pattern and variability of walking activity. We found 
that only for long ABs (≥ 60s) people with RBD walked with a higher proportion of short walking 
bouts (significantly higher alpha) and in shorter walking bouts compared to CL; also ROC analysis 
showed that only pattern (alpha) evaluated during long walking bouts played a role in 
discriminating RBD from CL, but did not give significant results during the regression analysis.  
This may reflect restricted engagement in sustained walking bouts for RBD. Comparison across 
studies however is difficult due to limited number of studies on RBD walking activity. 
Interestingly, this walking activity/ behavior “picture” seems very similar to the typical PD pattern 
of activity [38], characterized by an inability to sustain high level of walking and a walking pattern 
defined by shorter walking bouts compared to healthy controls. Our findings on Macro gait 
characteristics not only extend and partly corroborate previous work, but would underline already 
the risk and the tendency of people with RBD, in this prodromal “at high risk” phase, to align with 
and show a “PD-like” behavior, identifying an early risk in people with RBD. 
The data, however, suggest that the relationship of people at risk of developing PD and activity is 
more complex and influenced by duration of walking bouts, particularly longer duration bouts. 
Differences observed in patterns of walking through a reduction in longer walking bouts may be 
due to compensatory change to reduce risk (e.g. falls risk), possibly by reducing duration of 
walking bouts either by limiting access to the community or exercise, or may be due to fatigue 
related to RBD. Our correlations results could corroborate this “risk reduction” hypothesis as we 
showed that people with higher falls rate tended to walk less and in shorter bouts, although this 
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should be interpreted with caution as falls rate in this study was a self-reported measure related to 
the numbers of falls recalled in the six months prior to the assessment. 
 
An open question is whether people with RBD would walk less and in shorter bouts due to fatigue 
as a result of sleep disturbance or rather because they are developing parkinsonism and therefore 
“PD-like” behavior. Our results support the latter, as we have shown that a clinical marker of PD 
(MDS-UPDRS III) was significantly correlated with lower volume of walking and shorter bouts 
length, while Epworth Sleepiness Scale did not show any correlation with either Macro or Micro 
gait characteristics. Reduction in walking bout length in people with RBD may also be due to 
changes in patterns of walking behaviors indicating reduced confidence and a less varied walking 
“routine”. Compensatory strategies or higher attentional load (e.g. dual task) required for walking 
during real-world conditions may also play a role in modifying Macro level outcomes. Indeed, our 
correlation results showed that poorer cognition was significantly associated with poorer 
performance (lower volume of walking), although this is still unclear and further work is required 
to understand this relationship more fully. 
Macro characteristics such as the overall amount of walking is important as inactivity increases 
the risk of other age associated health care conditions– which increase the overall burden of disease 
– which acts almost as a double hit. This becomes very relevant especially because RBD 
participants have been shown to have increased burden of cardiovascular risk factors compared to 
both controls and PD patients[21] and in fact our results showed that health status (EQ-5D VAS 
Score) was positively correlated with volume of walking, so participants with “better” health status 
walked more. By maintaining/increasing habitual levels of activity, more generic benefits, 
protective to a population at high risk of PD may be conferred. 
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Micro gait differs between RBD and CL. 
Our results confirmed the hypothesis that people with RBD would show impaired gait compared 
to controls characterized by slower gait velocity, lower variability and lower cadence. Previous 
work in laboratory settings showed an association between RBD and gait variability as well as 
measures of rhythm [13].  In partial support of previous studies showing that slower step velocity 
(pace) and cadence (slower rhythm) appear to be a prodromal marker for PD, we found rhythm, 
step velocity and its variability to be lower in RBD participants [13]. This could be explained by 
the fact that people with RBD appear to be walking slower and with shorter steps, so with a more 
cautious walking pattern and therefore reduced step velocity variability. Conversely, people with 
PD show higher gait variability, so our results could suggest that there may be a change in the 
variability construct going from the prodromal stage to manifest disease: from lower gait 
variability in the prodromal phase to higher gait variability later when PD manifests. Higher 
variability in Micro gait characteristics may be advantageous or deleterious representing either 
compensatory adaptions to minimize risk, or impaired control and inability to minimize risk, 
respectively. Conversely lower variability in Macro gait characteristics (‘behavior’) may be 
deleterious - representing inability to engage and adapt in a wider variety of walking activities and 
presenting a cautious gait pattern [47]. Results from our correlations analysis corroborate this 
hypothesis; we showed that participants with poorer global cognition (lower MMSE scores) 
walked with higher step velocity variability and slower pace (lower step velocity and step length), 
and that participants with higher motor disease severity and lower motor functions (MDS-UPDRS 
III, Flamingo Test and Timed Up and Go Test) walked slower, with shorter steps and with lower 
variability (swing time variability, step length variability and step velocity variability). 
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In contrast to a previous study conducted in a high-risk cohort, we did not find increased gait 
asymmetry [18]. This could be due to the different protocol (study was conducted in a lab-based 
environment and not real-world conditions) and the different cohort (non-manifesting LRRK2-
G2019S mutation carrier vs. RBD). We speculate that when following up people with RBD and 
testing them longitudinally the tendency of higher variability and asymmetry may emerge, leading 
to a more “PD like” gait. 
 
In line with our hypothesis, we found that Micro gait characteristics played an important role in 
discriminating RBD from CL. We showed that pace, variability and rhythm characteristics were 
impaired in RBD and rhythm (swing time) was the best single discriminative domain in the 
regression model for Micro gait characteristics. This is interesting as the ability to regulate pace 
and rhythm (swing time) is notably impaired in PD and both domains have been shown to be dopa-
resistant sensitive measures of disease progression [52]. The lower pace and rhythm (poorer 
performance) of RBD compared to CL and the fact that swing time strongly discriminated RBD 
from CL would corroborate the theory that subtle changes in rhythm could reflect not only 
prodromal and early manifestation motor impairment, but also a potential powerful progressive 
marker of alterations to the central gait network in RBD [16, 52]. 
As a general comment, we did not achieve high sensitivity and specificity values; this in line with 
the high heterogeneity characterizing RBD populations. Indeed, within RBD participants some are 
on the verge of converting to PD, others may convert in >10 years’ time, and others may never 
convert. Recent work has described how olfactory dysfunction is an important clinical biomarker 
for PD [53].  We found that adding olfactory loss information (sniffin’ sticks test total scores) to 
gait characteristics increased discriminative power of the regression models, achieving highest 
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AUC for long ABs (AUC = 0.860). This suggests that a multimodal assessment could be a useful 
tool for discrimination of RBD from controls. Future work is needed to address this point by 
looking at larger cohorts and longitudinal data including converters to DLB, MSA, etc. which may 
have a different gait signature. 
 
Clinical Implications 
We found that more Micro gait characteristics than Macro ones seem to discriminate people with 
RBD from CL; specifically Micro gait pace, rhythm and variability measures seem to be best 
discriminative domains for presence of RBD. Real-world walking behavior and gait assessment 
could therefore play an important role, together with other prodromal biomarkers, as a diagnostic 
tool to identify at an early stage people with similar “PD-like” walking behaviors and gait profiles, 
so at risk of developing PD. 
 
Limitations 
This study informs understanding of the association between walking activity quantified via a 
range of Macro and Micro gait characteristics and RBD, however further work is required to 
identify the merits of these exploratory analysis, especially in a larger and balanced sample of 
people with RBD and in longitudinal studies looking at conversion to PD if and when available. 
We acknowledge that, due to male predominance of the presented cohort, generalisability of the 
results may not extend to females. Moreover, accounting for multiple correction may also 
strengthen and confirm results. Utilizing larger populations of RBD assessed longitudinally to 
enable separation of participants with high risk of converting to PD to those with lower risk may 
help improving discriminatory analysis and in ultimately predicting prodromal PD. We 
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acknowledge that the inclusion of only one model of gait including specific Macro and Micro gait 
characteristics may limit generalizability; in the future other reported models and outcomes should 
be considered to identify the best measure (or combination of measures) for the detection of early 
prodromal markers of PD.  
 
Conclusion 
We found that Macro gait outcomes, assessing overall walking behavior, do not seem to play a 
significant role in identifying or discriminating RBD, apart when considering longer walking 
bouts. In general longer bouts (≥ 60s) seem to differentiate groups better than medium or medium-
to-long bouts. Micro gait characteristics are sensitive to identify RBD; pace, variability and rhythm 
characteristics significantly differentiated RBD from controls, with swing time being the best 
discriminator for the definition of persons with RBD, so at risk of developing PD. Our results are 
promising and would suggest quantitative sensor-based real-world gait assessment as an important 
part of an assessment battery for definition of prodromal markers of PD. 
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Figures 
Figure 1.  
Real-world assessment – Macro and Micro gait characteristics: (a) Example of body worn monitor 
placement for the real-world (7-day) data collection. (b) Raw vertical acceleration processing 
(signal segments in black) from real-world data. (c) Example of walking bout extraction and Micro 
gait characteristic evaluation from walking bouts. (d) Data output: conceptual model of Macro gait 
representing three domains and six Macro gait characteristics, and Micro gait representing five 
domains and 14 Micro gait characteristics. 
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Figure 2.  
Radar plot illustrating the real-world Macro (panel a) and Micro (panel b) gait characteristics for 
controls (CL) and people with rapid eye movement sleep behavior disorder (RBD) evaluated in 
real-world conditions for total ambulatory bouts. The central dotted line represents CL data, 
deviation from zero along the axis radiating from the center of the plot represents how many 
standard deviations (range: ± 1 SD, z score based on CL means and standard deviations) the RBD 
differ from CL. * represents significant differences between RBD and CL (p values < 0.05). (Var: 
Variability, Asy: Asymmetry).  
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Figure 3. 
Radar plot illustrating the real-world Macro and Macro gait characteristics for controls (CL) and 
people with rapid eye movement sleep behavior disorder (RBD) evaluated in real-world conditions 
for short-to-medium (10s ≤ ABs < 30s, Macro - panel a, Micro - panel d), medium-to-long (30s ≤ 
ABs < 60s, Macro - panel b, Micro - panel e) and long ambulatory bouts (ABs ≥ 60s, Macro - 
panel c, Micro - panel f). The central dotted line represents CL data, deviation from zero along the 
axis radiating from the center of the plot represents how many standard deviations (range: ± 1 SD, 
z score based on CL means and standard deviations) the RBD differ from CL. * represents 
significant differences between RBD and CL (p values < 0.05). (Var: Variability, Asy: 
Asymmetry). 
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Figure 4. 
Receiver Operating Characteristics (ROC) results for regression models using gait only and 
olfactory loss information (sniffin’ sticks test total score) in addition to gait characteristics for 
total ambulatory bouts (Total ABs, panel a) and long ambulatory bouts (ABs ≥ 60s, panel b)). 
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Tables 
Table 1 
Clinical and demographic characteristics for controls (CL) and participants with rapid eye 
movement sleep behavior disorder (RBD). 
Characteristic 
CL (n = 34) RBD (n = 63) 
p 
Mean (SD) Mean (SD) 
Female (n, %) 0, 0% 5, 7.9% 0.092 
Age (years) 67.3 (10.1) 67.1 (9.4) 0.945 
BMI (kg/m2) 27.1 (3.0) 28.1 (5.5) 0.314 
MMSE (0-30) 28.6 (1.9) 26.9 (2.2) 0.001 
Duration of symptoms (years) - 4.5 (4.2) - 
MDS Probability of prodromal PD [%] - 85.2 (23.2) - 
Epworth Sleepiness Scale Total Score 
(0-24) 
5.3 (3.6) 7.0 (5.0) 0.079 
Sniffin’ Sticks Total Score (0-16) 12.2 (2.2) 8.1 (3.2) <0.001 
EQ-5D VAS Score 85.7 (9.9) 76.0 (17.6) 0.001 
MDS-UPDRS III 3.0 (2.5) 6.6 (6.7) <0.001 
Flamingo test (s) 25.3 (9.3) 22.2 (10.3) 0.154 
Purdue pegboard test (s) 34.1 (6.5) 30.8 (6.3) 0.018 
Timed Up and Go test (s) 8.0 (2.0) 9.3 (2.8) 0.019 
Falls rate 0.1 (0.3) 0.4 (0.8) 0.017 
BMI: Body Mass Index; MMSE, Mini–Mental State Examination; EQ-5D VAS score: EuroQol-5 Dimension VAS 
score; MDS-UPDRS III: Movement Disorders Unified Parkinson’s Disease Rating Scale part III; Falls Rate: number 
of falls reported in the six months before the assessment. In bold significant p-values (p <0.05).  
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Table 2. 
Real-world Macro gait characteristics (volume, pattern and variability) for controls (CL) and 
people with rapid eye movement sleep behavior disorder (RBD). Data are presented for total 
ambulatory bouts (ABs > three steps). Values are presented as mean ± standard deviation (SD). 
Results of the ANCOVA analysis between people with RBD and CL are reported, in bold are 
shown p-values < 0.05. 
Macro Characteristics Total ABs 
  CL RBD F-value p 
Volume     
Total Walking Time per Day  (Min) 209 (61) 210 (64) 0.252 0.617 
Percentage of Walking Time 15 (4) 15 (4) 0.252 0.617 
Number of steps per Day 14494 (4141) 14139 (4656) 0.006 0.940 
Bouts per Day 654 (191) 669 (174) 0.625 0.431 
Pattern     
Mean Bout Length (sec) 19 (4) 19 (3) 0.476 0.492 
Alpha (α) 1.588 (0.036) 1.585 (0.034) 0.290 0.592 
Variability     
Variability (S2) 0.889 (0.069) 0.872 (0.07) 1.172 0.282 
 
36 
 
Table 3. 
Real-world Micro gait characteristics for controls (CL) and people with rapid eye movement sleep 
behavior disorder (RBD). Data are presented for total ambulatory bouts (ABs > three steps). 
Values are presented as mean ± standard deviation (SD). Results of the ANCOVA analysis 
between people with RBD and CL are reported, in bold are shown p-values < 0.05. 
Micro Characteristics Total ABs    
  CL RBD F-value p 
Pace     
Step Velocity (m/s) 
1.084 
(0.091) 
1.037 
(0.073) 
5.994 0.016 
Step Length  (m) 
0.609 
(0.036) 
0.596 
(0.034) 
2.209 0.141 
Swing Time Var (s) 
0.145 
(0.016) 
0.148 
(0.012) 
0.906 0.344 
Variability     
Step Velocity Var (m/s) 
0.384 
(0.039) 
0.367 
(0.029) 
5.922 0.017 
Step Length Var (m) 
0.156 
(0.012) 
0.155 
(0.011) 
0.062 0.804 
Step Time Var  (s) 
0.174 
(0.021) 
0.176 
(0.013) 
0.226 0.635 
Stance Time Var (s) 
0.186 
(0.023) 
0.188 
(0.015) 
0.176 0.676 
Rhythm     
Step Time (s) 
0.602 
(0.026) 
0.613 
(0.021) 
5.496 0.021 
Swing Time (s) 
0.446 
(0.024) 
0.459 
(0.023) 
6.941 0.010* 
Stance Time (s) 
0.755 
(0.03) 
0.768 
(0.022) 
5.366 0.023 
Asymmetry    
 
Step Time Asy (s) 
0.095 
(0.016) 
0.094 
(0.009) 
0.719 0.399 
Swing Time Asy (s) 
0.086 
(0.014) 
0.085 
(0.009) 
0.662 0.418 
Stance Time Asy (s) 
0.096 
(0.016) 
0.094 
(0.009) 
0.862 0.356 
Postural Control    
 
Step Length Asy (m) 
0.085 
(0.009) 
0.086 
(0.008) 
0.313 0.577 
Var: Variability; Asy: Asymmetry. * p ≤ 0.01 
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Table 4 
Receiver Operating Characteristics analysis with Area Under the Curve (AUC) and binary logistic 
regression significant results with values of sensitivity, specificity and accuracy for the Macro and 
Micro gait characteristics. Data are presented for total ambulatory bouts (ABs > three steps) and 
ABs ≥ 60s. 
Total bouts AUC p 
Sensitivity 
at  90% 
specificity 
Specificity 
at 90% 
sensitivity  
Max accuracy 
(sensitivity, specificity) 
Regression (sensitivity, 
specificity, accuracy) 
Micro             
Pace       
Step Velocity (m/s) 0.648 0.016 14.30% 25.71% 63.33% (66.7%, 60.00%) 
88.9%, 31.4%, 68.4% 
p=0.023 (AUC = 0.698) 
Step Length  (m) 0.622 0.047 15.87% 17.14% 63.80% (61.9%, 65.71%)  - 
Variability       
Step Velocity Var 
(m/s) 
0.644 0.019 33.33% 17.14% 63.01% (31.7%, 94.28%) 
88.9%, 31.4%, 68.4% 
p=0.042 (AUC = 0.698) 
Rhythm       
Step Time (s) 0.622 0.047 22.22% 22.86% 61.27% (39.7%, 82.85%)  - 
Swing Time (s) 0.631 0.032 23.80% 22.86% 61.42% (85.7%, 37.14%)  - 
Stance Time (s) 0.620 0.050 22.22% 28.57% 59.68% (50.8%, 68.57%)  - 
Abs ≥ 60s  
Macro             
Pattern       
Mean Bout Length 
(sec) 
0.631 0.032 15.90% 34.29% 64.44% (88.90%, 40%)  - 
Alpha (α) 0.625 0.040 17.50% 37.14% 
65.40% (93.70%, 
37.14%) 
 - 
Variability       
Variability (S2) 0.623 0.045 17.50% 17.14% 
61.90% (66.70%, 
57.14%) 
 - 
Micro             
Pace       
Step Velocity (m/s) 0.625 0.041 12.70% 28.57% 
61.27% (96.80%, 
25.71%) 
 - 
Rhythm    
   
Step Time (s) 0.642 0.020 14.30% 22.86% 
64.44% (74.60%, 
54.29%) 
 - 
Swing Time (s) 0.652 0.013 19.00% 25.71% 
66.83% (50.80%, 
82.86%) 
93.7%, 20%, 67.3% 
p=0.011 (AUC = 0.660) 
Stance Time (s) 0.640 0.022 19.00% 25.71% 
63.49% (69.80%, 
57.14%) 
 - 
Var: Variability. In bold significant p-values for binary logistic regression analysis (p <0.05).  
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Table 5 
Partial correlations between Macro and Micro gait characteristics and clinical scales in RBD 
participants. Data displayed as (r (p value)). Data in bold refer to significant correlations (p < 0.05). 
Total bouts MMSE 
MDS 
Probability 
of 
prodromal 
PD 
Epworth 
Sleepiness 
Scale Total 
Score 
EQ-5D 
VAS 
Score 
MDS-
UPDRS 
III 
Flamingo 
test 
Timed 
Up and 
Go test  
Falls 
Rate 
Macro 
Characteristics        
Volume 
        
Total Walking 
Time per Day  
(Min) 
.227 
(.035) -.156 (.234) .018 (.862) 
.245 
(.019) 
-.286 
(.005)* 
.198 
(.056) 
-.330 
(.001)* 
-.343 
(.002)* 
Percentage of 
Walking Time 
.227 
(.035) -.156 (.234) .018 (.862) 
.245 
(.019) 
-.286 
(.005)* 
.198 
(.056) 
-.330 
(.001)* 
-.343 
(.002)* 
Number of steps 
per Day 
.250 
(.019) -.118 (.369) -.002 (.988) 
.240 
(.021) 
-.330 
(.001)* 
.205 
(.047) 
-.357 
(<.001)* 
-.306 
(.005)* 
Bouts per Day 
.167 
(.122) -.175 (.181) .001 (.989) 
.221 
(.034) 
-.181 
(.081) 
.092 
(.377) 
-.217 
(.035) 
-.261 
(.019) 
Pattern 
        
Mean Bout 
Length (sec) 
.157 
(.145) -.097 (.460) -.005 (.966) 
.112 
(.288) 
-.247 
(.016) 
.251 
(.015) 
-.259 
(.012) 
-.264 
(.017) 
Alpha (α) 
.021 
(.846) .125 (.340) -.073 (.492) 
-.020 
(.852) 
.106 
(.309) 
-.182 
(.078) 
.138 
(.185) 
.200 
(.073) 
Variability 
        
Variability (S2) 
.155 
(.151) -.035 (.790) -.050 (.637) 
.105 
(.318) 
-.227 
(.028) 
.178 
(.086) 
-.224 
(.030) 
-.203 
(.069) 
Micro 
Characteristics                 
Pace 
        
Step Velocity 
(m/s) 
.370 
(<.001)* -.066 (.618) -.068 (.522) 
.152 
(.147) 
-.362 
(<.001)* 
.337 
(.001)* 
-.455 
(<.001)* 
-.144 
(.199) 
Step Length  
(m) 
.394 
(<.001)* -.083 (.530) -.061 (.564) 
.189 
(.071) 
-.276 
(.007)* 
.323 
(.001)* 
-.379 
(<.001)* 
-.157 
(.161) 
Swing Time Var 
(s) 
-.190 
(.078) -.037 (.781) .119 (.258) 
-.164 
(.119) 
.149 
(.152) 
-.154 
(.139) 
.245 
(.017) 
.087 
(.437) 
Variability 
        
Step Velocity 
Var (m/s) 
.295 
(.006)* -.194 (.136) -.040 (.707) 
.029 
(.784) 
-.150 
(.150) 
.267 
(.009)* 
-.259 
(.012) 
-.122 
(.279) 
Step Length Var 
(m) 
.205 
(.057) -.252 (.052) -.096 (.361) 
.145 
(.167) 
-.119 
(.253) 
.203 
(.050) 
-.236 
(.022) 
-.115 
(.306) 
Step Time Var  
(s) 
-.153 
(.156) -.129 (.325) .143 (.172) 
-.168 
(.109) 
.075 
(.473) 
-.061 
(.559) 
.155 
(.136) 
.064 
(.572) 
Stance Time 
Var (s) 
-.125 
(.248) -.142 (.280) .142 (.176) 
-.193 
(.065) 
.061 
(.562) 
-.049 
(.642) 
.133 
(.202) 
.066 
(.556) 
Rhythm 
        
Step Time (s) 
-.143 
(.187) -.056 (.671) .050 (.635) 
-.026 
(.806) 
.241 
(.019) 
-.109 
(.295) 
.274 
(.008)* 
.015 
(.893) 
Swing Time (s) 
-.152 
(.159) .005 (.970) .094 (.370) 
-.114 
(.279) 
.245 
(.017) 
-.111 
(.288) 
.297 
(.004)* 
.031 
(.782) 
Stance Time (s) 
-.151 
(.163) -.074 (.572) .031 (.768) 
.027 
(.796) 
.211 
(.041) 
-.086 
(.407) 
.249 
(.016) 
-.007 
(.947) 
Asymmetry 
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Step Time Asy 
(s) 
.054 
(.617) -.127 (.333) .060 (.569) 
-.003 
(.979) 
-.084 
(.419) 
-.066 
(.529) 
-.032 
(.759) 
.059 
(.601) 
Swing Time 
Asy (s) 
.017 
(.877) -.128 (.331) .102 (.332) 
-.075 
(.479) 
-.036 
(.731) 
-.155 
(.135) 
.102 
(.327) 
.120 
(.287) 
Stance Time 
Asy (s) 
.051 
(.642) -.127 (.334) .121 (.249) 
-.038 
(.722) 
-.045 
(.664) 
-.115 
(.268) 
.030 
(.773) 
.093 
(.408) 
Postural 
Control         
Step Length 
Asy (m) 
.098 
(.367) -.092 (.486) .127 (.227) 
-.012 
(.908) 
.009 
(.930) 
-.025 
(.812) 
-.134 
(.198) 
.017 
(.879) 
MMSE, Mini–Mental State Examination; EQ-5D VAS score: EuroQol-5 Dimension VAS score; MDS-UPDRS III: 
Movement Disorders Unified Parkinson’s Disease Rating Scale part III; Var: Variability; Asy: Asymmetry. * p ≤ 0.01 
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Supplementary Table 1 
Real-world Macro gait characteristics (volume, pattern and variability) for controls (CL) and 
people with rapid eye movement sleep behaviour disorder (RBD). Data are presented for short-to-
medium (10s ≤ ABs < 30s, corresponding to a range of 15-50 steps), medium-to-long (30s ≤ ABs 
< 60s, corresponding to arrange of 50-100 steps) and long ambulatory bouts (ABs ≥ 60s, 
corresponding to ≥ 100 steps). Values are presented as mean ± standard deviation (SD). Results of 
the ANCOVA analysis between people with RBD and CL are reported, in bold are shown p values 
< 0.05. 
Macro 
Characteristics 
10s ≤ ABs < 30s 
(15 – 50 steps) 
30s ≤ ABs < 60s 
(50 – 100 steps) 
ABs ≥ 60s 
(≥ 100 steps) 
  CL RBD 
F-
value 
p CL RBD 
F-
value 
p CL RBD 
F-
value 
p 
Volume             
Total Walking 
Time per Day  
(Min) 
64 (20) 66 (18) 1.252 0.266 37 (15) 39 (14) 0.732 0.394 72 (30) 68 (34) 0.057 0.811 
Percentage of 
Walking Time 
4 (1) 5 (1) 1.252 0.266 3 (1) 3 (1) 0.217 0.642 5 (2) 5 (2) 0.409 0.524 
Number of steps 
per Day 
4040 
(1341) 
4139 
(1080) 
0.616 0.434 
2668 
(1076) 
2733 
(979) 
0.435 0.511 
6060 
(2302) 
5548 
(2942) 
0.262 0.610 
Bouts per Day 219 (69) 
228 
(60) 
1.313 0.255 54 (22) 56 (20) 0.674 0.414 29 (13) 29 (13) 0.097 0.756 
Pattern             
Mean Bout 
Length (sec) 
17 (0.4) 
17 
(0.4) 
0.208 0.649 41 (1) 41 (1) 0.908 0.343 
159 
(36) 
143 
(33) 
4.551 0.036 
Alpha (α) 
3.407 
(0.121) 
3.417 
(0.119) 
0.078 0.781 
4.838 
(0.322) 
4.781 
(0.262) 
1.201 0.276 
2.522 
(0.342) 
2.706 
(0.374) 
5.497 0.021 
Variability             
Variability (S2) 
0.298 
(0.006) 
0.296 
(0.006) 
3.234 0.075 
0.188 
(0.005) 
0.189 
(0.006) 
0.725 0.397 
0.612 
(0.115) 
0.564 
(0.122) 
3.024 0.085 
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Supplementary Table 2 
Real-world Micro gait characteristics for controls (CL) and people with rapid eye movement sleep 
behaviour disorder (RBD). Data are presented for short-to-medium (10s ≤ ABs < 30s, 
corresponding to a range of 15-50 steps), medium-to-long (30s ≤ ABs < 60s, corresponding to a 
range of 50-100 steps) and long ambulatory bouts (ABs ≥ 60s, corresponding to ≥ 100 steps). 
Values are presented as mean ± standard deviation (SD). Results of the ANCOVA analysis 
between people with RBD and CL are reported, in bold are shown p values < 0.05. 
Micro 
Characteristics 
 10s ≤ ABs < 30s 
(15 – 50 steps) 
  
 30s ≤ ABs < 60s 
(50 – 100 steps) 
  
 ABs ≥ 60s 
(≥ 100 steps) 
  
  CL RBD 
F-
value 
p CL RBD 
F-
value 
p CL RBD 
F-
value 
p 
Pace             
Step Velocity (m/s) 
1.026 
(0.069) 
1.009 
(0.059) 
1.634 0.204 
1.079 
(0.066) 
1.057 
(0.073) 
1.897 0.172 
1.146 
(0.162) 
1.078 
(0.109) 
4.660 0.033 
Step Length  (m) 
0.59 
(0.024) 
0.586 
(0.022) 
0.344 0.559 
0.611 
(0.023) 
0.607 
(0.03) 
0.066 0.797 
0.633 
(0.061) 
0.614 
(0.052) 
1.890 0.173 
Swing Time Var (s) 
0.156 
(0.014) 
0.156 
(0.01) 
0.155 0.695 
0.148 
(0.014) 
0.148 
(0.011) 
0.003 0.957 
0.127 
(0.03) 
0.133 
(0.021) 
1.124 0.292 
Variability             
Step Velocity Var 
(m/s) 
0.382 
(0.029) 
0.378 
(0.028) 
0.221 0.640 
0.375 
(0.028) 
0.363 
(0.03) 
3.387 0.069 
0.351 
(0.077) 
0.338 
(0.05) 
0.714 0.400 
Step Length Var 
(m) 
0.154 
(0.008) 
0.155 
(0.007) 
1.320 0.254 
0.15 
(0.01) 
0.149 
(0.01) 
0.043 0.837 
0.143 
(0.03) 
0.145 
(0.023) 
0.312 0.578 
Step Time Var  (s) 
0.185 
(0.018) 
0.184 
(0.011) 
0.000 0.986 
0.174 
(0.018) 
0.173 
(0.012) 
0.130 0.719 
0.154 
(0.039) 
0.16 
(0.026) 
0.619 0.433 
Stance Time Var (s) 
0.197 
(0.02) 
0.196 
(0.012) 
0.000 0.994 
0.185 
(0.02) 
0.185 
(0.013) 
0.058 0.811 
0.166 
(0.043) 
0.172 
(0.029) 
0.542 0.463 
Rhythm             
Step Time (s) 
0.620 
(0.024) 
0.624 
(0.023) 
0.938 0.335 
0.612 
(0.026) 
0.618 
(0.025) 
1.667 0.200 
0.585 
(0.042) 
0.603 
(0.027) 
5.612 0.020 
Swing Time (s) 
0.465 
(0.024) 
0.473 
(0.024) 
2.741 0.101 
0.456 
(0.025) 
0.465 
(0.027) 
2.664 0.106 
0.428 
(0.032) 
0.444 
(0.026) 
6.288 0.014 
Stance Time (s) 
0.774 
(0.027) 
0.777 
(0.023) 
0.522 0.472 
0.765 
(0.028) 
0.772 
(0.026) 
1.755 0.189 
0.739 
(0.049) 
0.761 
(0.03) 
6.067 0.016 
Asymmetry    
 
   
     
Step Time Asy (s) 
0.077 
(0.014) 
0.076 
(0.009) 
0.311 0.578 
0.042 
(0.008) 
0.042 
(0.007) 
0.248 0.619 
0.025 
(0.006) 
0.027 
(0.007) 
0.853 0.358 
Swing Time Asy (s) 
0.07 
(0.012) 
0.069 
(0.01) 
0.545 0.462 
0.038 
(0.008) 
0.038 
(0.007) 
0.544 0.463 
0.022 
(0.005) 
0.024 
(0.006) 
2.068 0.154 
Stance Time Asy 
(s) 
0.077 
(0.013) 
0.076 
(0.01) 
0.394 0.532 
0.042 
(0.009) 
0.042 
(0.007) 
0.162 0.688 
0.024 
(0.006) 
0.026 
(0.006) 
2.180 0.143 
Postural Control    
 
   
     
Step Length Asy 
(m) 
0.081 
(0.01) 
0.082 
(0.009) 
0.283 0.596 
0.05 
(0.008) 
0.051 
(0.008) 
0.260 0.612 
0.027 
(0.006) 
0.029 
(0.007) 
2.359 0.128 
Var: Variability; Asy: Asymmetry. 
